Intangible Assets, Net |
9 Months Ended | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||
| Intangible Assets, Net [Abstract] | |||||||||||||||||||||||||||||||||||||
| INTANGIBLE ASSETS, NET | NOTE 8 — INTANGIBLE ASSETS, NET
Net intangible assets consist of the following:
On November 5, 2024, the Company purchased a license of pharmaceutical distribution in Mainland China through its acquisition of 100% equity interest in Hupan Pharmaceutical. The Company recognized the distribution license as an intangible asset of $418,867 based on the assessment of fair value at the purchase date, adjusted by deferred taxes impact on temporary tax differences in an asset acquisition using the simultaneous equations method. The transaction was closed on November 21, 2024. impairment expense was recognized for the nine months ended March 31, 2026.
Amortization expense of $21,370 was recognized for the three months ended March 31, 2026. Amortization expense of $64,112 was recognized for the nine months ended March 31, 2026. |
||||||||||||||||||||||||||||||||||||